118 related articles for article (PubMed ID: 10769659)
1. Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism.
Hsieh TC; Wu JM
Anticancer Res; 2000; 20(1A):225-8. PubMed ID: 10769659
[TBL] [Abstract][Full Text] [Related]
2. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
3. Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells.
Sica G; Zelano G; Settesoldi D; Iacopino F
Anticancer Res; 2003; 23(2B):1283-7. PubMed ID: 12820384
[TBL] [Abstract][Full Text] [Related]
4. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines.
Hsieh TC; Wu JM
Exp Cell Res; 1999 May; 249(1):109-15. PubMed ID: 10328958
[TBL] [Abstract][Full Text] [Related]
5. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
7. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
8. Effects of vitamin C on androgen receptor mediated actions in human prostate adenocarcinoma cell line LAPC-4.
Wang MH; Abreu-Delgado Y; Young CY
Urology; 2003 Jul; 62(1):167-71. PubMed ID: 12837460
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells.
Mitchell SH; Zhu W; Young CY
Cancer Res; 1999 Dec; 59(23):5892-5. PubMed ID: 10606230
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
[TBL] [Abstract][Full Text] [Related]
11. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
[TBL] [Abstract][Full Text] [Related]
12. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES.
Hsieh T; Chen SS; Wang X; Wu JM
Biochem Mol Biol Int; 1997 Jul; 42(3):535-44. PubMed ID: 9247711
[TBL] [Abstract][Full Text] [Related]
13. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells.
Gao S; Liu GZ; Wang Z
Prostate; 2004 May; 59(2):214-25. PubMed ID: 15042621
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
15. Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer.
Blok LJ; Chang GT; Steenbeek-Slotboom M; van Weerden WM; Swarts HG; De Pont JJ; van Steenbrugge GJ; Brinkmann AO
Br J Cancer; 1999 Sep; 81(1):28-36. PubMed ID: 10487609
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
He D; Falany CN
Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
18. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
19. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells.
He ML; Yuan HQ; Jiang AL; Gong AY; Chen WW; Zhang PJ; Young CY; Zhang JY
Cancer; 2006 Jun; 106(12):2547-55. PubMed ID: 16691616
[TBL] [Abstract][Full Text] [Related]
20. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
